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Abstract
Purpose The paediatric sickle cell disease (SCD) osteomyelitis 
(OM) incidence is 0.3% to 12%. Differentiating vaso- occlusive 
crises (VOC) from OM is a diagnostic challenge, with limited 
evidence guiding management. We present a 15-year review 
of a paediatric sickle cell cohort. We aim to identify OM inci-
dence and provide a management protocol for these children 
presenting with bone pain.
Methods A prospective database of children with haemoglo-
binopathies (2002 to 2017) was analyzed for temperature, 
C-reactive protein (CRP) and white cell count (WCC) on ad-
mission as well as imaging, treatment and cultures. OM di-
agnosis was supported by imaging and blood cultures. VOC 
was defined as bone pain that improved without antibiotics.  
Results Over 15 years, 96 children with SCD presented 358 
times to hospital. Empirical antibiotics were given in 308 
presentations. There were five cases of OM (1.4%); two 
acute and three chronic. In all, 50 presentations of VOC were 
identified. No significant differences in age were noted be-
tween the OM and VOC group. Temperature and CRP were 
significantly elevated in the OM group with no significant 
difference in WCC. Cultures were only positive in the chron-
ic OM admissions. There were no cases of septic arthritis. No 
surgical intervention was required.
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Conclusion In children with SCD presenting with persistent 
bone pain, fever, elevated CRP and WCC, OM should be sus-
pected and prompt antibiotic treatment started. Our treat-
ment pathway was successful avoiding OM in 98.6% and 
septic arthritis in 100%. Further research on novel biological 
markers distinguishing OM from VOC should be investigated.
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Introduction
Sickle cell disease (SCD) is an autosomal recessive haemo-
globinopathy causing a chronic haemolytic anaemia. It is 
one of the most common severe monogenic disorders in 
the world.1-3 The prevalence of SCD is highest in sub-Sa-
haran Africa, where it is estimated to affect almost 1% 
of children born each year.1,4 Although the incidence in 
Europe is significantly lower, prevalence of SCD has been 
steadily increasing due to migration. Subsequently, new-
born screening was introduced in the United Kingdom in 
2006.5-7
In SCD, red blood cells form abnormal, rigid, cres-
cent-shaped sickle cells. This causes occlusion of the 
microvascular circulation and subsequent tissue hypoxia. 
Hypoxia of tissues causes a secondary inflammatory reac-
tion, resulting in increased intramedullary pressure and 
bone pain.1,8
Individuals with SCD are susceptible to a variety of 
osteoarticular complications throughout their life. These 
include painful vaso-occlusive crises (VOC), dactylitis, 
osteomyelitis (OM), avascular necrosis and septic arthri-
tis.9,10 Due to the combination of ischaemia and impaired 
immunity, children with SCD are more susceptible to bac-
terial infections affecting bones and joints, causing OM 
and septic arthritis.11-14 Salmonella and Staphylococcus 
SICKLE CELL VASO-OCCLUSIVE CRISIS VERSUS OSTEOMYELITIS
34 J Child Orthop 2019;13:33-39
aureus species are reported as the most common caus-
ative organisms of OM in SCD.9,12,13,15 There is limited pub-
lished data on the incidence and prevalence of OM within 
the paediatric SCD population in Europe and North Amer-
ica. The reported incidence of OM ranges from 0.36% to 
3% across adults and children with SCD and other hae-
moglobinopathies.10,11,16 The incidence of septic arthritis is 
reported to be 0.2% in children with SCD.10
Children with SCD frequently experience bone and 
joint pain and VOCs have been shown to be 50-times 
more common than OM in children with SCD.17 However, 
the two disease processes may initially present with sim-
ilar symptoms and signs, including bone pain, fever and 
restriction in joint movement.18,19
Early recognition and prompt treatment of OM is 
essential to minimize serious complications. However, dif-
ferentiating between VOC and early OM is a diagnostic 
challenge and there are limited validated diagnostic tools 
to help make this distinction. Unwarranted antibiotic treat-
ment may result in morbidity, antibiotic resistance and 
increased cost.18 However, delayed antibiotic treatment in 
OM has been shown to be a risk factor for relapse, slow 
recovery and poor outcome.20-22
Multiple diagnostic algorithms have been proposed 
to guide practice. Some include clinical findings and bio-
chemical parameters alone 18,21 whilst others incorporate 
imaging such as ultrasound19 or magnetic resonance 
imaging (MRI),23,24 to improve decision-making. 
The modern approach to children with SCD, present-
ing with bone pain, fever and raised inflammatory mark-
ers, is a low threshold for empirical antibiotic treatment 
whilst awaiting confirmation with positive culture results 
or findings on imaging.10,25 This has led the pathway 
adopted at our institution since 2002. In this paper, we 
aim to provide a pragmatic protocol of assessment and 
management of children with SCD presenting with bone 
pain combining clinical, biochemical, microbiological and 
radiological findings (Fig. 1).
This study aims to identify the incidence of OM in a 
large cohort of children with SCD that were treated 
according to our hospital protocol. In addition, the study 
aims to provide a clinical pathway for managing children 
with SCD and bone pain.
Materials and methods
A prospective database of paediatric patients with hae-
moglobinopathies under the care of our regional referral 
centre was created in 2002. This is a referral centre for all 
sickle cell patients in the South West London region. Study 
inclusion criteria were all patients with a confirmed diag-
nosis of homozygous SCD up to and including the age of 
18 years at the time of presentation. Individuals with other 
haemoglobinopathies were excluded. 
The medical notes of all patients meeting the inclusion 
criteria were reviewed to identify each acute presentation 
to hospital with bone pain. The data extracted included: 
1) gender and age at presentation; 2) temperature, 
C-reactive protein (CRP) and white cell count (WCC) at 
presentation; and 3) blood culture results, radiographic 
imaging and any surgical interventions.
Cases of OM were confirmed radiologically with MRI 
and or with positive blood cultures. 
The VOC cohort was defined as: bone pain in the 
absence of trauma that improved with conservative treat-
ment as an inpatient according to our Trust protocol with-
out administration of antibiotics (Fig. 1).
Our hospital protocol of empirical antibiotic treat-
ment for suspected OM consisted of intravenous admin-
istration of antibiotics for two weeks followed by an oral 
course of four weeks pending clinical improvement. In 
chronic OM, treatment began with six weeks of intrave-
nous antibiotics. Children under five years old received 
ceftriaxone and children over five years old received 
flucloxacillin (Fig. 1). IV treatment can be continued in 
the community with aid of the outpatient parenteral 
antimicrobial therapy service with on-going clinical 
monitoring and treatment course dependent on clinical 
improvement.
The primary outcome was the rate of identified cases of 
OM and septic arthritis under the current treatment proto-
col in children presenting with bone pain. The secondary 
outcomes were the difference in WCC, temperature and 
CRP between the two groups at presentation. 
Local audit approval was gained for the purpose of the 
study.
Statistical analysis
Non-parametric statistics were suitable for analysis. Nor-
mality was assessed by the Kolmogorov-Smirnov test. 
Descriptive statistics were used for calculating of fre-
quencies, sd and the mean in the normally distributed 
cohort. For skewed variables the interquartile range and 
the median were utilized. The Mann-Whitney U test was 
used to compare the continuous variables between the 
two groups and the Pearson chi-square was used for the 
non-continuous variable. Significance was set at p < 0.05. 
Analyses were performed using the   IBM SPSS Statistics 
for Windows, Version 23.0., IBM Corp., Armonk, New 
York.
Results
The 15-year database from October 2002 to December 
2017 comprised of 177 children with haemoglobinopa-
thies. In all, 96 patients had homozygous SCD and met 
the inclusion criteria. Children with SCD presented a total 
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Fig. 1 Hospital protocol of assessment and management of children with sickle cell disease (SCD) presenting with bone pain (FBC, 
full blood count; BC, blood culture; WCC, white cell count; NSAIDS, non-steroidal anti-inflammatory drugs; OM, osteomyelitis; VOC, 
vaso-occlusive crisis; Abx, antibiotics; USS, ultrasound scan; IV, intravenous; TDS, three times a day; OD, oral dose; QDS, once a day).
of 358 times with bone pain during the study period. 
In all, 97% of children with SCD presented at least once 
during the study period, with a mean of 3.8 presentations 
per patient.
Of the 358 presentations with bone pain, empirical 
antibiotics were given in 308 cases. There were 50 cases 
that improved without administration of empirical antibi-
otics and five cases of OM confirmed by cultures or imag-
ing (1.4% of total presentations) (Fig. 2). There were two 
acute cases of OM that involved the humerus and pelvis, 
respectively, and three presentations of a flare up of a 
known chronic tibial OM. There were no cases of septic 
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arthritis. Neither of the two acute cases went on to require 
surgical intervention whereas the chronic case had been 
operated on in a different country before data collection 
began. Blood cultures were positive in two presentations 
in the child with chronic OM (Pseudomonas stutzeri and 
Staphylococcus aureus). 
The two acute cases responded well to antibiotic 
treatment with no complications. The chronic case also 
improved with no immediate complications. All cases 
completed six weeks of antibiotic treatment. 
The comparison of WCC, CRP and temperature of 
the OM and VOC groups is presented in Table 1. Pyrexia 
occurred significantly more frequently in the OM group, 
presenting with a median temperature of 37.8°C com-
pared with 36.9°C in the VOC group. CRP was signifi-
cantly higher in the OM group (51.4 mg/dL versus 7.8 mg/
dL). White blood cell count was also higher in the OM 
group (15.8 versus 14.4), however, the difference did not 
reach statistical significance.
There was no statistically significant difference in 
patient age at presentation between the OM and VOC 
cohorts (median age ten years versus eight years). All five 
OM cases occurred in female patients, and 25 of the 50 
VOC cases were female.
Discussion
In this study, early administration of empirical antibiot-
ics to children with SCD who presented with bone pain 
resulted in a very low incidence of OM and no cases of 
septic arthritis. The results support the current protocol 
of treatment developed in our hospital based on years of 
experience in treating SCD that was successful in preven-
tion of septic arthritis in 100% and OM in 98.6% of pre-
sentations with bone pain. 
There is limited published data on the incidence and 
prevalence of OM and septic arthritis within the paediatric 
SCD population in Europe and northern America. Cham-
bers et al10 have focused specifically on osteoarticular 
infections in children with SCD and reported a 0.5% inci-
dence of OM and 0.2% incidence of septic arthritis across 
22 years in their population in Georgia, North America. 
Piehl et al11 studied the incidence of OM in both adults 
and children with SCD and reported a 0.36% annual inci-
dence across 13 years in South Carolina, North America. 
Telfer et al16 analyzed clinical outcomes in a cohort of 250 
children with a variety of haemoglobinopathies, identify-
ing eight episodes of OM in seven children across 2158 
patient years of observation.16 This last study was based in 
East London, making it likely to be an equivalent popula-
tion to our study. 
In this study, there were five cases of confirmed OM in 
three children among a cohort of 96 children with SCD 
during a 15-year period (1.4% of presentations with bone 
pain). Of these five cases, there were two acute cases 
affecting the pelvis and humerus which were diagnosed 
on clinical findings and MRI. No positive blood cultures 
were recorded in these cases. The three presentations of 
one child with chronic tibial OM were confirmed with 
positive cultures (Pseudomonas stutzeri and Staphylococ-
cus aureus) and MRI imaging. 
The low diagnostic yield of blood cultures among our 
cohort is unsurprising given it has been reported that a 
causative pathogen may not be identified in 33% to 55% 
of cases of OM.26-28 Given the small cohort size and only 
Fig. 2 Flow diagram depicting the vaso-occlusive crisis (VOC) and osteomyelitis (OM) cohorts (SCD, sickle cell disease; Abx, antibiotics).
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two positive cultures in one child, it is unsurprising that 
there were no cases of Salmonella species, which has 
been the most prevalent causative organism of OM in 
SCD reported in the literature.9,12,13 No bone biopsies were 
taken in our cohort. Although bone biopsies were once 
heralded as the ‘benchmark’ diagnostic tool, they have 
recently been shown to be similarly low-yield to blood 
cultures and not without procedural risks.29,30
In this study, there were 50 cases of VOC which were 
defined as bone pain that improved without empirical 
antibiotics. Comparing the VOC cases with OM cases, a 
non-significant increase in WCC was seen on admission 
in the OM group (median 15.8 versus 14.4 × 109/L). In 
contrast, CRP and temperature were both significantly 
elevated in the OM group (median CRP 51.4 mg/dL versus 
7.8 mg/dL, median temperature 37.8°C versus 36.9°C).
In clinical practice, a VOC is a diagnosis of exclusion in 
children with SCD who present with localized bone pain 
that improves with fluids, analgesia and anti-inflamma-
tory drugs as per the treatment protocol in Figure 1.4,17-
19,31 From this protocol one can conclude that an afebrile 
patient with a low CRP is treated as a VOC with continued 
close assessment for any change. Differentiating between 
VOC and early OM is a diagnostic challenge and imaging 
techniques are often used to aid clinical diagnosis. MRI is 
a useful adjunct to clinical findings and has been shown 
to be highly sensitive in diagnosing OM.23,24,32,33 However, 
differentiation between bony infarction, and acute and 
chronic OM on MRI is extremely difficult.18,31,34 Although 
MRI is readily available at our tertiary centre, its specific-
ity is low and must be interpreted alongside clinical and 
biochemical findings. The cost of MRI use should also be 
weighed against the potential diagnostic yield in these 
cases.
Combining imaging and biological markers can aid in 
differentiating a VOC from OM. Although CRP was signifi-
cantly elevated in the OM group in our study, it is limited 
as it is a non-specific marker of inflammation and/or infec-
tion. 
There is emerging evidence that pro- and anti-inflam-
matory cytokines may provide novel biological markers 
to aid diagnosis. Altered cytokine expression in OM in 
SCD has been suggested and the role of interleukin (IL)-
10, a Th2 cytokine demonstrating anti-inflammatory and 
immunomodulatory properties,35,36 in the pathogenesis of 
OM has further been studied. Decreased IL-10 values have 
been associated with an increased risk of OM since lower 
levels of the anti-inflammatory cytokine were reportedly 
noted in affected patients.37 Future prospective studies 
could elaborate further on the link between IL-10 and OM 
in SCD and explore its role in OM diagnosis and follow-up.
This study gives some insight into the morbidity asso-
ciated with SCD in children. In all, 97% of children with 
SCD presented at least once during the 15-year study 
period, with 3.8 presentations per patient on average. 
The musculoskeletal complications affecting children with 
SCD contribute to significant morbidity throughout child-
hood and adulthood.9,10,31 Painful crises result in missed 
school days, disruption to social activities and may affect 
mood and quality of life.38-40 Further research in this area 
is needed.
Strengths of this study include the large patient cohort 
over a 15-year period. Patients were from a broad geo-
graphic area of South West London, and hence likely 
representative of the Greater London paediatric SCD 
population. Electronic patient records meant availability 
and accuracy of historical blood test results, cultures and 
imaging results. 
The study is limited by the small number of cases of 
OM identified. Although it is reassuring that our current 
protocol results in a low infection rate, it limits the com-
parison between the OM and VOC group. Children who 
presented with bone pain and received early antibiotics 
may have had VOC or indeed an emerging OM that was 
halted by the early administration of empirical antibiotics. 
We can only confirm that the known combined clinical, 
biochemical and radiological parameters may be sugges-
tive of OM rather than suggest any novel individual diag-
nostic tool. 
Although the potential impact of bone and joint infec-
tions seem to outweigh the impact of over treatment with 
antibiotics, future prospective studies could shed a light 
on the adverse outcomes of over-use of empirical antibiot-
ics – leading to increased morbidity, antibiotic resistance 
and healthcare cost. Such future studies could provide 
a clearer insight to clinical parameters that differentiate 
between VOC and OM and aid healthcare professionals in 
distinguishing between these two clinical entities.
Table 1 Comparison of white cell count, C-reactive protein and temperature between osteomyelitis and vaso-occlusive crises groups. Data presented as median 
(interquartile range)
Variable Osteomyelitis group (n = 5) Vaso-occlusive crisis group (n = 50) p-value
Age (yrs) 10 8 0.559
Gender (M:F) 0:5 25:25 0.032
White cell count (109/L) 15.8 (3.25) 14.4 (7.10) 0.45
C-reactive protein (mg/L) 51.4 (52.40)  7.8 (22.63) 0.007
Temperature (°C) 37.8 (1) 36.9 sd 0.5 0.010
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Conclusion
This study reaffirms that clinicians should suspect OM in 
SCD children presenting with bone pain that is persistent 
and accompanied by fever and raised inflammatory mark-
ers. Early empirical antibiotics resulted in a low rate of OM 
and no septic arthritis.
The musculoskeletal manifestations of SCD continue 
to be a cause of significant morbidity for children, which 
may affect their education attainment, physical and men-
tal health. Prospective work is needed to explore this area 
and to identify predicative factors to aid clinicians in mak-
ing the challenging differentiation between OM and VOC. 
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